Oligonucleotide CDMO: From Preclinical To Commercial

Oligonucleotide therapeutics are expanding rapidly, bringing greater demand for development models that can manage chemical complexity, large‑scale synthesis, and stringent quality requirements. This flyer highlights a modern approach to oligonucleotide manufacturing that integrates flexible synthesis platforms, advanced impurity‑control strategies, and comprehensive analytical capabilities. Development teams gain access to scales ranging from milligram quantities to kilogram‑level output, supported by specialized equipment suites that enable consistent production of ASOs, siRNA, aptamers, and conjugated formats such as GalNAc and AOC.

The content also outlines how structured CMC strategies streamline progression through IND and NDA stages — emphasizing impurity pathway evaluation, PAR/CPP studies, genotoxicity assessments, and raw‑material specification setting. Purification options, including orthogonal chromatographic combinations and large‑scale lyophilization, provide multiple routes to achieve high purity and low endotoxin levels.

A section on enzymatic ligation shows how convergent assembly can improve yield, reduce N‑1 impurities, and elevate product quality compared to traditional solid‑phase synthesis. Readers will find practical insight into the tools, workflows, and scientific considerations that support reliable scale‑up and regulatory readiness.